How Raman Spectroscopy Is Benefitting Developing And Developed Countries - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

How Raman Spectroscopy Is Benefitting Developing And Developed Countries


Pharmaceutical Technology Europe
Volume 22, Issue 7

The full version of this counterfeiting feature can be read in the July issue of our digital magazine: http://www.pharmtech.com/ptedigital0710


Duane Sword
To date, the pharmaceutical industry's primary defence to counterfeiting is to create more sophisticated packaging that makes imitation more difficult, such as packaging involving barcoding and RFID. However, counterfeiters are becoming increasingly sophisticated and this approach ultimately only secures the packaging rather than the product itself. Also, implementing an RFID strategy can be very costly from an operational standpoint because it requires additional manpower and also introduces some technology hurdles that must be overcome before it can be more broadly applied. For example, each individual pallet or package requires an individual RFID chip, which despite decreasing prices, still costs about 7–15 cents. In the case of the Viagra implementation in 2006, Pfizer ultimately spent $5 million on just the pilot phase of their RFID tagging initiatives.1 Additionally, there are also unsettled questions about whether the RF energy used to read the tags may impact sensitive biologics.2

One analytical technique that has gained significant traction in the fight against counterfeits is Raman spectroscopy, which was originally created for use in condensed matter physics and chemistry where it was used to study vibration, rotational and other low-frequency modes in a system. The biggest difference between Raman spectroscopy and RFID is that the former tests the actual drug and/or raw materials, which is important for markets where the product is sold without its original packaging. Raman spectroscopy also accurately identifies chemicals through sealed glass, plastic bottles, plastic bags and blister packs, which means that the operator does not come into direct contact with the substance. This avoids potential contamination and preserves the integrity of any evidence that can be used against counterfeiters.

In recent years, Raman spectroscopy has become available as a lightweight, handheld instrument that can identify even slight differences in drug formulations. This type of instrument can be deployed to authenticate the raw materials and/or finished products on the spot at points throughout the supply chain, including:
  • Ports of inspection — to allow enforcement to execute random sample testing of raw materials and finished products before they enter the supply chain, thereby eliminating the risk to consumer health.
  • Distributors — by making handheld analytical instruments available at massive distribution centers, businesses can catch counterfeit materials and/or drugs before they are sent to the various worldwide locations, after which they can be very difficult to track and recall should a problem be identified at a later point in time.
  • Point of sale — conducting field inspections at the point of sale is the critical place where these instruments should be deployed to ensure counterfeit drugs are not ending up in the hands of patients. Additionally, these inspections send a clear message to counterfeiters because they are done publicly at pharmacies and open markets.

The problems in developing countries

The World Health Organisation (WHO) estimates that counterfeit pharmaceutical levels range from less than 1% in the developed world to more than 30% in less developed regions. In less developed countries, there are gaps throughout the supply chain because standards are not as strict as they are in more developed regions. Open markets, where the unauthorised re-sale of medicines often takes place, are also very prevalent in these regions.

Bringing technologies to less developed countries should be a top priority, and these technologies should ideally be portable and easy to use with minimal training, which handheld Raman instruments may be able to offer.

Some countries already have an anti-counterfeiting strategy in place. For instance, Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) has launched a text messaging service called the Mobile Authentication Service (MAS) that allows anyone in Nigeria to check the authenticity of their medicines. More than 80% of the population in Africa have mobile phones, which makes systems such as these highly accessible to the general public.

In combination with its MAS system, Nigeria is also using our handheld Raman instruments to identify even the slightest difference in drug formulation. After just two weeks of deployments, the instruments had helped authorities seize more than 60000 counterfeit drugs.3 The technology was also used to help NAFDAC intercept a consignment of counterfeit Lonart DS anti-malarial tablets worth 10 million naira.3 Arrests were made in connection with the incident, which sends a clear message to counterfeiters that there will be consequences.

Nigeria's aggressive anti-counterfeiting campaign is now being emulated in other developing countries. For instance, Indonesia's national agency for food and drug control (BPOM) is now using TruScan and others are also evaluating the technology.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here